N/A N=50 Time Limited Eating in Adolescents (Time LEAd): a Pilot Study
Obesity, Childhood
Primary: Percent Change in BMI in Excess of the 95th Percentile (%BMIp95) — -3.27; -3.76; -4.85 percent — p=0.4
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Tenecteplase in Patients With COVID-19
COVID-19 · Respiratory Failure · ARDS
Primary: Number of Participants Free of Respiratory Failure — 5; 2 Participants
Phase 1 N=91 Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area
Zika Virus Infection
Primary: Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for All Participants — 15; 22; 10; 18 Participants
N/A N=160 Neurobehavioral Plasticity to Regular Sugar-Sweetened Beverage Intake: An fMRI Experiment
Obesity · Weight Gain
Primary: Change in Voxel-wise Blood Oxygen Level Dependent (BOLD) Including Outliers Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals in Response to…
Phase 2 N=108 Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
N/A N=255 Evaluating and Improving the Sustainability of State-level Tobacco Control Programs in the United States
Program Sustainability · Tobacco Use
Primary: Change in Program Sustainability Assessment Tool (PSAT) Sustainability Scores — 4.9; 5.1; 3.8; 4.2 score on a scale
Phase 2 N=14 Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
Healthy
Primary: Oculo-Cognitive Addition Test (OCAT) Completion Time — 57.22; 57.22; 59.56; 58.18 seconds
Phase 2 N=66 Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
Alopecia Areata
Primary: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 58.44; 51.96 percent change
Phase 2 N=24 A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Advanced Gynecological Cancers · Ovarian Cancer · Cervical Cancer
Primary: Number of Treatment-emergent AEs of Vigil + Atezolizumab — 0; 0; 0; 0 adverse events
Phase 3 N=26 Emergency Treatment of Coral Snake Envenomation With Antivenom
Coral Snake Bite · Toxic Effect of Coral Snake Venom
Primary: Number of Participants Who Survived — 25 Participants
N/A N=72 Developing a Deliberate Practice Intervention to Recalibrate Physician Heuristics in Trauma Triage
Trauma Injury
Primary: Percentage of Participants Who Signed up for the Intervention That Completed All 3 Coaching Sessions. — 28; 0; 2; 0 Participants
N/A N=32 Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure
Heart Failure With a Preserved Ejection Fraction · Heart Failure, Diastolic · Chronotropic Incompetence
Primary: Change in Oxygen Consumption (VO2) at Ventilatory Anaerobic Threshold (VAT) — 10.4; 10.7 ml/kg/min
Phase 2 N=73 Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 10; 32 Participants
Phase 2 N=235 An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
Malignant Solid Tumor
Primary: Number of Participants With Drug Related AEs, SAEs, AEs Leading to Discontinuation and Deaths. — 7; 4; 3; 4 Participants
Phase 4 N=40 Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Chronic Sinusitis · Nasal Obstruction · Turbinate; Hypertrophy Mucous Membrane
Primary: Bleeding VAS - POD1 — 5.03; 4.82 score on a scale — p=0.8